Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth? | Front Oncol;12: 996554, 2022. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?

Britt, Alec S; Huang, Caitlyn; Huang, Chao H.

Affiliation

Britt AS; University of Kansas Comprehensive Cancer Center, Westwood, KS, United States.
Huang C; Pembroke Hill High School, Kansas City, MO, United States.
Huang CH; University of Kansas Comprehensive Cancer Center, Westwood, KS, United States.

Front Oncol ; 12: 996554, 2022.

Article in En | MEDLINE | ID: mdl-36523973

Key words

checkpoint inhibition therapy; definition; hyperprogression; mechanism; non-small cell lung cancer

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: United States Country of publication: Switzerland

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: United States Country of publication: Switzerland